The Cooper Companies, Inc. COO SPXR3KPHARMA
Company Overview
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Why Investors Should Care
Net profit has compounded at 11.0% per year over the last five years.
Carries low leverage with a debt-to-equity ratio of 0.33.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Oct 2025 Revenue of $4.09B (+5.1% YoY); net profit $374.90M.
- Trailing 12 Months Year-on-year growth — revenue +7.9%, earnings -4.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.3%, profit CAGR 11.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.35% |
| 1 Year: | 7.90% |
Compounded Profit Growth
| 5 Years: | 10.96% |
| 1 Year: | -4.44% |
Stock Price Performance
| 1 Year: | -6.30% |
| 6 Months: | -9.09% |
| 3 Months: | +3.34% |
| 1 Month: | -5.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.26 · Neutral
P/E of 58.97 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 11.0% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 59.0.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | COO The Cooper Companies, Inc. SPXR3KPHARMA | 69.59 | 58.97 | $13.57B | 0.00% | 6.05% | 2.85% | 8.35% | 10.96% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2015 | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Oct 2016 | Jan 2017 | Apr 2017 | Jul 2017 | Oct 2017 | Jan 2018 | Apr 2018 | Jul 2018 | Oct 2018 | Jan 2019 | Apr 2019 | Jul 2019 | Oct 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Oct 2020 | Jan 2021 | Apr 2021 | Jul 2021 | Jan 2022 | Apr 2022 | Jul 2022 | Jan 2023 | Apr 2023 | Jul 2023 | Jan 2024 | Apr 2024 | Jul 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 590.00M | 631.30M | 660.00M | 651.50M | 628.10M | 654.30M | 679.40M | 691.60M | 646.20M | 524.90M | 578.20M | 681.60M | 680.50M | 719.50M | 763.40M | 787.20M | 829.80M | 843.40M | 858.50M | 877.40M | 930.20M | 931.60M | 942.60M | 1.00B | 964.70M | 1.00B | 1.06B | 1.07B | 1.02B | 1.08B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 323.20M | 368.30M | 414.30M | 328.90M | 346.10M |
| Gross Profit | 272.90M | 253.30M | 262.00M | 298.50M | 316.60M | 296.00M | 312.40M | 343.90M | 356.20M | 353.40M | 370.90M | 404.50M | 426.80M | 430.00M | 418.50M | 432.60M | 450.70M | 455.00M | 426.50M | 323.50M | 360.80M | 424.00M | 450.70M | 487.10M | 516.10M | 518.40M | 532.50M | 552.10M | 558.50M | 582.90M | 610.00M | 623.80M | 631.20M | 663.00M | 660.20M | 679.10M | 692.00M | 650.80M | 695.20M | 735.40M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 494.30M | 516.30M | 510.40M | 482.40M | 766.40M |
| Operating Income | 50.31M | - | 57.40M | 89.80M | 102.70M | - | 90.70M | 117.10M | 112.80M | - | 90.20M | 74.70M | 115.60M | - | 110.90M | 146.90M | 142.20M | - | 111.10M | 28.60M | 72.00M | - | 133.40M | 143.20M | 100.60M | 130.80M | 132.70M | 140.60M | 149.50M | 96.30M | 151.60M | 153.10M | 161.70M | 192.50M | 182.00M | 184.80M | 175.70M | 140.40M | 212.80M | -31.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 261.30M | 272.70M | 239.60M | 310.10M | 67.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.20M | 25.40M | 24.40M | 22.40M | 20.90M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 144.50M | 151.90M | 116.80M | 192.20M | -48.40M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 56.80M | 53.60M | 32.20M | 61.40M | 29.50M |
| Net Income | 45.00M | 36.70M | 51.40M | 74.10M | 87.90M | 60.50M | 75.80M | 104.90M | 103.60M | 88.60M | -122.50M | 60.90M | 100.80M | 100.60M | 103.20M | 122.40M | 120.10M | 121.00M | 90.50M | 11.50M | 55.20M | 81.20M | 2.10B | 117.50M | 615.80M | 95.30M | 126.60M | 98.40M | 84.60M | 39.80M | 85.30M | 81.20M | 88.90M | 104.70M | 104.30M | 87.70M | 98.30M | 84.60M | 130.80M | -77.90M |
| Diluted EPS | 0.91 | 0.75 | 1.05 | 1.52 | 1.79 | 1.23 | 1.53 | 2.12 | 2.09 | 1.78 | -2.50 | 1.23 | 2.03 | 2.02 | 2.07 | 2.45 | 2.40 | 2.42 | 1.82 | 0.23 | 1.12 | 1.64 | 42.31 | 2.36 | 12.37 | 1.91 | 2.55 | 1.98 | 0.43 | 0.20 | 0.43 | 0.41 | 0.44 | 0.52 | 0.52 | 0.44 | 0.49 | 0.43 | 0.66 | -0.40 |
| R&D Expense | 18.30M | - | 14.80M | 16.70M | 15.90M | - | 16.30M | 16.80M | 17.50M | - | 18.80M | 20.80M | 22.50M | - | 21.00M | 21.00M | 21.50M | - | 22.20M | 23.80M | 21.80M | - | 21.40M | 21.00M | 24.80M | 26.20M | 26.30M | 28.70M | 31.60M | 32.60M | 36.50M | 39.50M | 38.90M | 39.00M | 40.70M | 45.50M | 44.60M | - | 44.30M | 42.50M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.05B | 1.08B | 1.16B | 1.33B | 1.45B | 1.59B | 1.72B | 1.80B | 1.97B | 2.14B | 2.53B | 2.65B | 2.43B | 2.92B | 3.31B | 3.59B | 3.90B | 4.09B |
| Gross Profit | 610.03M | 596.49M | 676.72M | 804.80M | 924.01M | 1.03B | 1.09B | 1.07B | 1.17B | 1.37B | 1.63B | 1.76B | 1.53B | 1.96B | 2.14B | 2.36B | 2.60B | 2.68B |
| Operating Income | 126.96M | 149.86M | 189.91M | 227.56M | 283.40M | 305.94M | 306.49M | 236.70M | 324.10M | 429.10M | 403.10M | 546.70M | 311.80M | 505.80M | 507.60M | 533.10M | 705.70M | 682.90M |
| Net Income | 63.96M | 100.55M | 112.80M | 175.43M | 248.34M | 296.15M | 269.86M | 203.50M | 273.90M | 372.90M | 139.90M | 466.70M | 238.40M | 2.94B | 385.80M | 294.20M | 392.30M | 374.90M |
| Diluted EPS | 1.42 | 2.21 | 2.43 | 3.63 | 5.05 | 5.96 | 5.51 | 4.14 | 5.59 | 7.52 | 2.81 | 9.33 | 4.81 | 59.16 | 1.94 | 1.48 | 1.96 | 1.87 |
| R&D Expense | 35.47M | 33.30M | 35.27M | 43.58M | 51.73M | 58.83M | 66.26M | 69.60M | 65.40M | 69.20M | 84.80M | 86.70M | 93.30M | 92.70M | 110.30M | 137.40M | 155.10M | 172.20M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2007 | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 2.55B | 2.53B | 2.62B | 2.94B | 3.14B | 4.46B | 4.46B | 4.48B | 4.86B | 6.11B | 6.27B | 6.74B | 9.61B | 11.49B | 11.66B | 12.32B | 12.39B |
| Total Equity | 1.46B | 1.42B | 1.54B | 1.67B | 1.94B | 2.19B | 2.40B | 2.57B | 2.67B | 2.70B | 3.18B | 3.31B | 3.63B | 3.82B | 6.94B | 7.17B | 7.55B | 8.08B | 8.24B |
| Cash & Equivalents | 3.23M | 1.94M | 3.93M | 3.57M | 5.17M | 12.84M | 77.39M | 25.20M | 16.40M | 100.80M | 88.80M | 77.70M | 89.00M | 115.90M | 95.90M | 138.20M | 120.80M | 107.60M | 110.60M |
| Long Term Debt | - | - | 771.63M | 591.98M | 327.45M | 348.42M | 301.67M | 1.28B | 1.11B | 1.11B | 1.15B | 1.99B | 1.26B | 1.38B | 1.40B | 2.35B | 2.52B | 2.55B | 2.46B |
| Total Liabilities | - | - | 1.01B | 858.24M | 687.03M | 728.23M | 713.77M | 1.87B | 1.79B | 1.78B | 1.68B | 2.81B | 2.65B | 2.91B | 2.66B | 4.32B | 4.11B | 4.23B | 4.16B |
| Current Liabilities | - | - | 175.41M | 199.52M | 267.21M | 262.55M | 321.25M | 442.18M | 568.78M | 543.20M | 396.10M | 536.50M | 1.11B | 1.00B | 732.10M | 1.28B | 969.00M | 1.02B | 1.11B |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 96.53M | 223.13M | 267.66M | 336.28M | 315.12M | 415.93M | 454.82M | 390.90M | 509.60M | 593.60M | 668.90M | 713.20M | 486.60M | 738.60M | 692.40M | 607.50M | 709.30M | 796.10M |
| Investing Cash Flow | -128.76M | -98.64M | -106.60M | -161.68M | -238.47M | -189.92M | -1.35B | -287.90M | -418.70M | -381.30M | -1.52B | -351.30M | -364.50M | -450.30M | -1.83B | -449.00M | -764.60M | -372.90M |
| Financing Cash Flow | 31.20M | -122.74M | -161.57M | -172.87M | -68.44M | -161.60M | 842.16M | -106.70M | -1.40M | -227.90M | 844.40M | -351.40M | -95.50M | -311.40M | 1.19B | -173.90M | 39.20M | -425.90M |
| Capital Expenditure | -124.89M | -93.91M | -73.76M | -103.67M | -99.78M | -178.13M | -238.06M | -243.00M | -152.60M | -127.20M | -193.60M | -292.10M | -310.40M | -214.40M | -242.00M | -392.50M | -421.20M | -362.40M |
| Free Cash Flow | -28.36M | 129.22M | 193.91M | 232.62M | 215.34M | 237.80M | 216.76M | 147.90M | 357.00M | 466.40M | 475.30M | 421.10M | 176.20M | 524.20M | 450.40M | 215.00M | 288.10M | 433.70M |
| Share Buybacks | - | - | 0 | 0 | 71.15M | 167.33M | 75.78M | 67.30M | 0 | 55.00M | 0 | 156.10M | 47.80M | 24.80M | 78.50M | 0 | 0 | 290.10M |
Ratios (Annual)
Figures in %.
| Metric | Oct 2008 | Oct 2009 | Oct 2010 | Oct 2011 | Oct 2012 | Oct 2013 | Oct 2014 | Oct 2015 | Oct 2016 | Oct 2017 | Oct 2018 | Oct 2019 | Oct 2020 | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 58.2% | 55.2% | 58.4% | 60.5% | 63.9% | 64.7% | 63.5% | 59.6% | 59.6% | 63.9% | 64.4% | 66.2% | 63.1% | 66.9% | 64.7% | 65.6% | 66.6% | 65.5% |
| Operating Margin % | 12.1% | 13.9% | 16.4% | 17.1% | 19.6% | 19.3% | 17.8% | 13.2% | 16.5% | 20.1% | 15.9% | 20.6% | 12.8% | 17.3% | 15.3% | 14.8% | 18.1% | 16.7% |
| Net Margin % | 6.1% | 9.3% | 9.7% | 13.2% | 17.2% | 18.7% | 15.7% | 11.3% | 13.9% | 17.4% | 5.5% | 17.6% | 9.8% | 100.8% | 11.7% | 8.2% | 10.1% | 9.2% |
| ROE % | 4.5% | 6.5% | 6.8% | 9.1% | 11.3% | 12.3% | 10.5% | 7.6% | 10.2% | 11.7% | 4.2% | 12.9% | 6.2% | 42.4% | 5.4% | 3.9% | 4.9% | 4.6% |
| ROCE % | - | 6.3% | 8.2% | 9.7% | 10.6% | 10.9% | 7.6% | 6.1% | 8.2% | 9.6% | 7.2% | 10.6% | 5.4% | 5.7% | 5.0% | 5.0% | 6.2% | 6.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.71% | 15.03M | $1.07B |
| 2 | Vanguard Capital Management LLC | 6.54% | 12.76M | $908.04M |
| 3 | State Street Corporation | 4.56% | 8.89M | $632.89M |
| 4 | Vanguard Portfolio Management LLC | 4.45% | 8.67M | $617.02M |
| 5 | T. Rowe Price Investment Management, Inc. | 3.81% | 7.43M | $528.76M |
| 6 | Browning West Lp | 3.69% | 7.20M | $512.10M |
| 7 | Price (T.Rowe) Associates Inc | 2.86% | 5.58M | $397.10M |
| 8 | Kayne Anderson Rudnick Investment Management LLC | 2.78% | 5.43M | $386.47M |
| 9 | Geode Capital Management, LLC | 2.75% | 5.36M | $381.46M |
| 10 | Franklin Resources, Inc. | 2.61% | 5.10M | $362.75M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for COO
How Will Cooper Companies Stock React To Its Upcoming Earnings? - Trefis
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNV2d0b1JyOVJNOFZwOFlhOEFKdlZDU2pPdWFWUkdaNmtaSy1kSUNEeG4wcVhYQ3AxdVF6cmgyMmhJY1paNDdBcXp6X0wyUWdfNHBUcWJYVGo4QWdxYkdCT0Z5MDZvWHA1SmljSEl5M25YZWwyZ3JiVXNhR1dqTE5lbEMtcGZTTlhnTUcwZz…
Cooper Companies (COO) Stock Trades At A Premium To Fair Value - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOdXZNVWJSellHNUljaE1ZT1B5bVFrTWlHVGpHWUZqLXJ0UVhrbEtJVkVTNk1pS21BQW9UV3NfNVpidE5xZ05hUlVCNVdibmNxUDZlM1JnNEo1Zk5nS3AwSmhoaTNiVDllaVlXV1FiNEVTZ0V1cEtPU3cxMFhXUUMwRExNZEZ1NUxGQ2VGRm…
RKLB Stock Suffers Worst Selloff In 2 Years — President, COO, Other Insiders Cashed Out $18M After Record Highs - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNUTd0WTZiUktJRFZoSzRrYk1Qb2pWak9scUdzR0hoMDVuRWJwWFFGd0FPODI5RjllVU1DZ1lBbWctQmVIQngyYmM2RFUxdEVCR3FQc3ZGT2MzRE42LWl0NDktcml0RTlTaFNOMUhuVkh4S0l6U1B6NVYtOVNqRWU1WkY3RVAzTXZjbmVmam…
Grab COO Dumps 145,000 Company Shares After the Stock's 28% One-Year Decline - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNQ3dEV2RHcE1xNUpLTm9UWjBhWXR1bk1yU2NUUlhmekw5MG1RRVZDUC01QmowRDNlaG1yb0xjcFMzWl9CWGVhMjE5S2pYX3Q4eDRHVDU4MWZuN2wzWTJDTmNpSERDNzBrU0FlTHpDNjFQYnY1LU9pUEMyQUtXU1Joa3ZBUGlodjRWem1oNX…
How Investors May Respond To Cooper Companies (COO) Analyst Forecasts Of Segment-Driven Earnings And Revenue Growth - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPMG9RbVJOMGQwd0UyZDZCTnVfbVFndlEzNVd6bVBqc1JZN2R5b3hkOVBQVTJnNjZaRFZtYmg5bFdsVzg1QTEwWWtrSThfRHA1TUZKcHhTdUFsNGU4RnZsWk9PLS1WUnNOSTZYQnFFTjhXSVZ6R2NwLXVIZlV4SXBwOGNISkVXdXFpMnRDNn…
(COO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxORTFnV3ZtZGdiLTlvLTBncnZSVEx6YWViZmpCQmFKYXgxQnd5TXZIYUtsV0VzUXdZclFQUWJWNkl1TlZBaFNDc1pFdHh6QW9vU1hPOEdLVG5xUXdjUzcwQ09RZnc1VlRONmtaa0FVMDhiR0o5TlJNcFluOTZoRWgxdlFJdkhJaVZma3hmME…
COO — Frequently Asked Questions
What is the current share price of The Cooper Companies, Inc. (COO)?
As of 2026-09-07 16:24 PDT, The Cooper Companies, Inc. (COO) trades at $69.59 on NasdaqGS. Its 52-week range is $58.98 to $84.32.
What is the market capitalisation of COO?
The Cooper Companies, Inc. (COO) has a market capitalisation of $13.57B on NasdaqGS.
What is the P/E ratio of COO?
COO trades at a trailing price-to-earnings (P/E) ratio of 58.97. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.76.
What is the return on equity (ROE) of COO?
COO has a return on equity (ROE) of 2.85%. Its return on capital employed (ROCE) is 6.05%.
Is COO a good stock to buy?
This page provides a data-driven analysis of The Cooper Companies, Inc. (COO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.